Form 8-K - Current report:
SEC Accession No. 0001193125-25-045585
Filing Date
2025-03-04
Accepted
2025-03-04 16:06:11
Documents
15
Period of Report
2025-03-03
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d909911d8k.htm   iXBRL 8-K 25205
2 EX-99.1 d909911dex991.htm EX-99.1 11738
6 GRAPHIC g909911g0304231454904.jpg GRAPHIC 2997
  Complete submission text file 0001193125-25-045585.txt   164462

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgnx-20250303.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgnx-20250303_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgnx-20250303_pre.xml EX-101.PRE 10807
17 EXTRACTED XBRL INSTANCE DOCUMENT d909911d8k_htm.xml XML 3500
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37553 | Film No.: 25704264
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)